IL175372A0 - Solid amorphous dispersions of an mtp inhibitor for treatment of obesity - Google Patents

Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Info

Publication number
IL175372A0
IL175372A0 IL175372A IL17537206A IL175372A0 IL 175372 A0 IL175372 A0 IL 175372A0 IL 175372 A IL175372 A IL 175372A IL 17537206 A IL17537206 A IL 17537206A IL 175372 A0 IL175372 A0 IL 175372A0
Authority
IL
Israel
Prior art keywords
obesity
treatment
solid amorphous
mtp inhibitor
amorphous dispersions
Prior art date
Application number
IL175372A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL175372A0 publication Critical patent/IL175372A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
IL175372A 2003-11-14 2006-05-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity IL175372A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14
PCT/IB2004/003581 WO2005046644A1 (en) 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Publications (1)

Publication Number Publication Date
IL175372A0 true IL175372A0 (en) 2006-09-05

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175372A IL175372A0 (en) 2003-11-14 2006-05-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Country Status (16)

Country Link
US (1) US20080293801A1 (enExample)
EP (1) EP1696887A1 (enExample)
JP (1) JP2007511500A (enExample)
KR (1) KR20060096076A (enExample)
CN (1) CN1878538A (enExample)
AR (1) AR048206A1 (enExample)
AU (1) AU2004289110A1 (enExample)
BR (1) BRPI0416596A (enExample)
CA (1) CA2545443A1 (enExample)
CO (1) CO5690536A2 (enExample)
IL (1) IL175372A0 (enExample)
MX (1) MXPA06005489A (enExample)
NO (1) NO20062778L (enExample)
NZ (1) NZ546677A (enExample)
TW (1) TW200515909A (enExample)
WO (1) WO2005046644A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631694A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
EP2522657B1 (en) 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Indole derivative
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
DE69222847T3 (de) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
TNSN03146A1 (fr) * 2001-06-28 2005-12-23 Pfizer Prod Inc Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b).
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
JP2007511500A (ja) 2007-05-10
US20080293801A1 (en) 2008-11-27
AU2004289110A1 (en) 2005-05-26
TW200515909A (en) 2005-05-16
CN1878538A (zh) 2006-12-13
BRPI0416596A (pt) 2007-01-30
MXPA06005489A (es) 2006-08-11
EP1696887A1 (en) 2006-09-06
CA2545443A1 (en) 2005-05-26
KR20060096076A (ko) 2006-09-05
WO2005046644A1 (en) 2005-05-26
AR048206A1 (es) 2006-04-12
CO5690536A2 (es) 2006-10-31
NO20062778L (no) 2006-08-14
NZ546677A (en) 2008-11-28

Similar Documents

Publication Publication Date Title
IL193451A0 (en) Surgical devices for treating pelvic conditions
IL183329A0 (en) Jnk inhibitors for treatment of cns injury
IL189659A0 (en) Ikk inhibitors for the treatment of endometriosis
EP1756092A4 (en) NEW INHIBITORS OF RHO-KINASEN
EP1549316A4 (en) HAMMER OF TFGbeta
ZA200800036B (en) Mao-B inhibitors useful for treating obesity
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1602376A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF ADIPOSITAS
IL178100A0 (en) 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
MX2007005153A (es) Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero.
GB0422439D0 (en) Inhibitors of infection
EP1812078A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY
IL175372A0 (en) Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
IL176628A0 (en) Treatment of aromatase inhibitor therapy-related osteoporosis
IL179779A0 (en) Sludge treatment process
PL380068A1 (pl) Sposób obróbki szlamu
EP1906952A4 (en) MAO-B INHIBITORS USEFUL IN THE TREATMENT OF OBESITY
ZA200807615B (en) Renin inhibitors for the treatment of hypertension
GB0410502D0 (en) Treatment of metakaolin
ZA200604680B (en) Process for the preparation of tubulin inhibitors
GB0407635D0 (en) Process for assembly of electronic devices
EP1973558A4 (en) METHODS OF TREATING OBESITY WITH ENTEROSTATIN
GB0411014D0 (en) Methods for the control treatment and management of obesity
GB2421239B (en) Treatment of sewage sludge
GB2398069B (en) Treatment of ferrous waste